Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending July 11, 2008. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, specifically regarding changes in their interests in Ordinary Share ADRs.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. The document is a regulatory disclosure of a specific transaction rather than a financial performance report.
Material Changes
The filing details a change in the interest of Dr. D. Pulman in Ordinary Share ADRs. The increase resulted from the re-investment of dividends paid to shareholders on July 10, 2008, under the Annual Investment Plan feature of the GlaxoSmithKline Executive Supplemental Savings Plan. The transaction occurred at a price of $48.40 per ADR.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the disclosure of the specific director transaction in accordance with Disclosure and Transparency Rule 3.1.4R(1)(a).
Key Facts for Investor Verification
- Transaction Date: July 11, 2008 (Notification date); July 10, 2008 (Dividend payment date).
- Individual Involved: Dr. D. Pulman.
- Transaction Type: Increase in ADR interest via dividend re-investment.
- Price per ADR: $48.40.
- Plan Involved: GlaxoSmithKline Executive Supplemental Savings Plan (Annual Investment Plan feature).